Skip to main content
SpringerLink
Log in

Targeted Screening and Treatment of Chronic Kidney Disease

Lessons Learned from the Kidney Early Evaluation Program

  • Practical Disease Management
  • Published:
Disease Management & Health Outcomes

Abstract

The National Kidney Foundation’s (NKF) Kidney Early Evaluation Program (KEEP) is a public service program that addresses the gaps in chronic kidney disease (CKD) awareness and care. This free, voluntary, community-based program is designed to screen people at risk of CKD and promote CKD awareness among primary healthcare providers and the public. The primary objective of KEEP is to identify individuals at risk of CKD at a time when appropriate intervention has the potential to markedly slow and potentially prevent progression to kidney failure, as well as to reduce cardiovascular events.

The specific opportunities for disease management are improvements in early recognition and treatment to prevent cardiovascular disease (CVD), slow kidney disease progression, treat co-morbidities and complications, and enhance preparation for dialysis and kidney transplantation. Disease management also poses opportunities to improve CKD care by aligning healthcare providers to prevent fragmentation.

KEEP involves a health questionnaire and a diagnostic panel of blood and urine tests to establish the diagnosis of CKD and detect CKD complications and co-morbid conditions. Three key tests are blood pressure, spot urine albumin-to-creatinine ratio, and estimated glomerular filtration rate derived from serum creatinine. To date, 75 000 participants aged ≥18 years with a history of diabetes mellitus (25%) or hypertension (52%) or a family history of these diseases and/or kidney disease (24%) have attended KEEP screenings across the US in 49 of 50 states. The 2006 KEEP annual data report notes the prevalence of the five CKD stages to be 3% (stage 1), 5% (stage 2), 20% (stage 3), and 1% (stages 4 and 5), which confirms the ability of this targeted screening program to detect CKD early. Only 2% of KEEP participants are aware of CKD, and 29% meet diagnostic criteria. Low awareness of CKD exists in a high-risk US population. Mass or untargeted screening is anticipated to reveal CKD rates similar to that observed in the National Health and Nutrition Examination Survey (approximately 13%). Targeted screening allows for efficient and cost-effective disease management to improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table III
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Coresh J, Byrd-Holt D, Astor B, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180–8

    Article  PubMed  Google Scholar 

  2. US Renal Data System. USRDS 2005 annual data report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005

    Google Scholar 

  3. Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come. Kidney Int 2006; 69: 781–2

    Article  PubMed  Google Scholar 

  4. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ 2006; 332: 563–4

    Article  PubMed  Google Scholar 

  5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1–266

    Article  Google Scholar 

  6. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–701

    PubMed  CAS  Google Scholar 

  7. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–83

    Article  PubMed  CAS  Google Scholar 

  8. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–100

    Article  PubMed  Google Scholar 

  9. Myers G, Miller W, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52: 5–18

    Article  PubMed  CAS  Google Scholar 

  10. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112–19

    Article  PubMed  CAS  Google Scholar 

  11. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489–95

    Article  PubMed  Google Scholar 

  12. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305

    Article  PubMed  CAS  Google Scholar 

  13. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–95

    Article  PubMed  CAS  Google Scholar 

  14. Nissenson AR, Collins AJ, Dickmeyer J, et al. Evaluation of disease-state management of dialysis patients. Am J Kidney Dis 2001; 37: 938–44

    Article  PubMed  CAS  Google Scholar 

  15. Chen RA, Scott S, Mattern WD, et al. The case for disease management in chronic kidney disease. Dis Manag 2006; 9: 86–92

    Article  PubMed  Google Scholar 

  16. Trivedi HS, Pang MM, Campbell A, et al. Slowing the progression of chronic renal failure: economic benefits and patients’ perspectives. Am J Kidney Dis 2002; 39: 721–9

    Article  PubMed  Google Scholar 

  17. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996; 19: 1051–61

    Article  PubMed  CAS  Google Scholar 

  18. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62 Suppl. 82: 68–72

    Google Scholar 

  19. Stevens LA, Fares G, Fleming J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 2005; 16: 2439–48

    Article  PubMed  Google Scholar 

  20. Buckalew Jr VM, Berg RL, Wang SR, et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996; 28: 811–21

    Article  PubMed  Google Scholar 

  21. Collins AJ, Li S, Ma JZ, et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38: S26–9

    Article  PubMed  CAS  Google Scholar 

  22. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999; 10: 1281–6

    PubMed  CAS  Google Scholar 

  23. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137: 479–86

    PubMed  Google Scholar 

  24. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program. Am J Kid Dis 2003; 42: 22–35

    Article  PubMed  Google Scholar 

  25. Brown WW, Collins A, Chen S, et al. Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program, Kidney Int, 2003; 63: S50–5

    Article  Google Scholar 

  26. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–69

    Article  PubMed  Google Scholar 

  27. National Kidney Foundation. Kidney Early Evaluation Program. Am J Kidney Dis 2005; 45: S1–135

    Google Scholar 

  28. National Kidney Foundation. Kidney early evaluation program: 2006 annual data report. Am J Kidney Dis 2007. In press

  29. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2004; 43: S1–290

    Google Scholar 

  30. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72

    Article  PubMed  CAS  Google Scholar 

  31. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  32. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  33. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41: S1–76

    Google Scholar 

  34. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 2004; 14: 64–71

    Article  PubMed  Google Scholar 

  35. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S1–145

    Google Scholar 

  36. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67: 1483–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Ortho Biotech Chronic Care, Abbott Laboratories, Novartis Pharmaceuticals Corporation, Bayer Healthcare, and Lifescan provide funding to support the Kidney Early Evaluation Program. Joseph Vassalotti, Leslie Gracz-Weinstein, and Monica Gannon are all employees of the National Kidney Foundation. The authors have no other conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. National Kidney Foundation, New York, New York, USA

    Joseph A. Vassalotti, Leslie Gracz-Weinstein &  Wendy Weinstock Brown (Chief of Staff, Professor of Medicine)

  2. Mount Sinai School of Medicine, New York, New York, USA

    Joseph A. Vassalotti

  3. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    Monica R. Gannon

Authors
  1. Joseph A. Vassalotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie Gracz-Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monica R. Gannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wendy Weinstock Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy Weinstock Brown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vassalotti, J.A., Gracz-Weinstein, L., Gannon, M.R. et al. Targeted Screening and Treatment of Chronic Kidney Disease. Dis-Manage-Health-Outcomes 14, 341–352 (2006). https://doi.org/10.2165/00115677-200614060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200614060-00004

Keywords

Search

Navigation